Antithrombin-lowering in hemophilia: a closer look at fitusiran

ALN-AT3SC - Creative Biolabs

PDF] An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B

Fitusiran prophylaxis leads to 61% reduction in bleeds among people with hemophilia A or B

Tailoring the effect of antithrombin-targeting therapy in haemophilia A using in silico thrombin generation

Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity

PDF) Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy

Full article: Managing Severe Hemophilia A in Children: Pharmacotherapeutic Options

RNAi for the treatment of people with hemophilia

Tailoring the effect of antithrombin-targeting therapy in haemophilia A using in silico thrombin generation